QuiaPEG Pharmaceuticals operates in medical technology. The company has developed a technological platform that is used to improve and develop existing pharmaceuticals. The technology is based on what is known as PEGylation, a technique that connects water-soluble polymers with the pharmaceuticals and is used to improve various characteristics in the biopharmaceuticals in regards to stability and resistance.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Bio Vitos Norge AS | 25,30 | 25,30 | 2024-12-20 |
| Bo Nordlander | 15,68 | 15,68 | 2025-06-26 |
| Norvolt AS | 9,96 | 9,96 | 2025-06-26 |
| Sami Sinno | 2,88 | 2,88 | 2025-06-26 |
| Johan Keisu | 2,19 | 2,19 | 2025-06-26 |
| Gunnela Kristina M Blomqvist | 2,16 | 2,16 | 2025-06-26 |
| Martin Berglund | 1,89 | 1,89 | 2025-06-26 |
| Avanza Pension | 1,71 | 1,71 | 2025-06-26 |
| Olle Svedåker | 1,54 | 1,54 | 2025-06-26 |
| Jeanette Fogelberg | 1,47 | 1,47 | 2025-06-26 |
